T ranscatheter aortic valve implantation (TAVI) is as an effective treatment alternative for patients with severe aortic stenosis who are either inoperable or high risk, for surgical aortic valve replacement (AVR). 1,2 Several short-term 3 and medium-term 4 outcome studies have consistently demonstrated good clinical outcomes after TAVI, findings that have been reinforced by more recent long-term follow-up data. 5, 6 As a result, the number of TAVI implants performed worldwide continues to grow year on year. 7 Several imaging techniques can be used to assess whether a patient is suitable for TAVI 8 ; echocardiography remains the fundamental method of assessing the severity of aortic valve disease, permitting measurements of left ventricular (LV) and right ventricular (RV) functions, aortic valve area (AVA), mean and peak pressure gradients across the aortic valve, and myocardial mass. 9 Two other imaging modalities are widely used in the preassessment of potential TAVI patients: multislice computerized tomography, which provides information on aortic annular Background-Cardiovascular magnetic resonance (CMR) can provide important structural information in patients undergoing transcatheter aortic valve implantation. Although CMR is considered the standard of reference for measuring ventricular volumes and mass, the relationship between CMR findings of right ventricular (RV) function and outcomes after transcatheter aortic valve implantation has not previously been reported. Methods and Results-A total of 190 patients underwent 1.5 Tesla CMR before transcatheter aortic valve implantation.
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dimensions and potential access routes, 8 and x-ray angiography, which delineates coronary and aortic root anatomy.
Cardiovascular magnetic resonance (CMR) is the current gold standard for the assessment of myocardial volumes and mass, 10, 11 and by using gadolinium contrast, is uniquely able to provide information on myocardial fibrosis, infarction, and infiltration. 12 However, research into the role of CMR in assessing TAVI patients has largely been limited to annulus sizing. 13 Therefore, the purpose of this study was to examine the relationship between CMR measurements in patients being considered for TAVI and long-term clinical outcomes after the procedure.
Methods

Study Population
The study population comprised 190 patients who underwent TAVI at the Royal Brompton Hospital, United Kingdom, between 2007 and 2012. Since the beginning of our TAVI program in 2007, all patients accepted for the procedure have undergone CMR provided that (1) there were no contraindications to performing CMR (eg, a permanent pacing system), (2) patients consented to having the scan performed, and (3) patients were able to tolerate and complete the scan. All cases were formally discussed at a multidisciplinary team meeting-which included cardiothoracic surgeons, cardiologists, and radiologists-and all available imaging was reviewed. All patients gave written informed consent before the procedure and were followed up prospectively in a dedicated outpatient facility at 6 weeks, 6 months, 12 months, and thereafter yearly, unless they requested to be seen at their referring hospital. Demographic and clinical data were taken from in-house TAVI databases, from which data are fed to a national TAVI registry.
The primary end point of the study was all-cause mortality. Mortality data were obtained from hospital notes and the National Strategic Tracing Service-a national database for all National Health Service patients in the United Kingdom.
Echocardiography
A diagnosis of critical aortic stenosis was made using 2-dimensional (2D) transthoracic echocardiography performed before the TAVI procedure. Echocardiography was performed by an experienced echocardiographer specialized in the assessment of aortic valve disease, and who was blinded to the patient's treatment status. All echocardiograms were saved on a digital database. AVA was estimated using the continuity equation (AVA=left ventricular outflow tract area ×[velocity time integral left ventricular outflow tract /velocity time integral valve ]).
Cardiovascular Magnetic Resonance
CMR was performed using a 1.5-Tesla scanner (Magnetom Sonata or Avanto, Siemens, Erlangen, Germany) and a standardized protocol with stable study parameters. Steady-state free precession breathhold cines (echo time/repetition time, 1.6/3.2 ms; flip angle, 60°) were used for aortic valve planimetry and for the assessment of LV volumes and mass.
Late gadolinium enhancement (LGE) images were acquired 10 to 15 minutes after the injection of 0.01 mmol/kg gadolinium (GD-DTPA; Schering, Germany) in identical short-axis and long-axis planes using an inversion-recovery gradient echo sequence as previously described. 14 Inversion times were adjusted to null normal myocardium (usual range, 280-440 ms; pixel size 1.7×1.4 mm. To exclude artifact, LGE imaging was repeated for each short-axis slice in 2 separate phase-encoding directions.
Ventricular volumes and function were analyzed using semiautomated software (CMR tools; Cardiovascular Imaging Solutions, London, United Kingdom); endocardial and epicardial contours were semiautomatically traced in end systole and end diastole. LV mass was calculated from the total end-diastolic myocardial volume multiplied by the specific gravity of the myocardium (1.05 g/mL). LV mass and volumes were indexed to body surface area, age, and sex and were considered abnormal if they were outside the 95th percentile. 15 Impaired RV systolic function (RVSD) was defined as an RV ejection fraction (RVEF <50%). To verify the reproducibility and reliability of RV functional assessment by CMR in this cohort, interobserver variability was calculated for RVEF measurements in 25 randomly selected patients by using the measurements obtained by an independent observer blinded to all other analyses.
The severity of aortic stenosis was assessed using CMR-derived planimetry of the AVA, a technique that has previously been validated against echocardiographic measures of aortic stenosis severity, 16 and was graded according to American College of Cardiology/ American Heart Association guidelines, is as follows: mild, >1.5 cm 2 , moderate, 1.5 to 1.0 cm 2 , and severe, <1.0 cm 2 . 17 The presence of LGE was assessed by 2 independent observers who were blinded to all clinical data.
Transcatheter Aortic Valve Implantation
Selection and technical aspects of TAVI were consistent with published guidelines. 18 Both the Medtronic CoreValve (Medtronic, Minneapolis, MN) and Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA) were implanted. The decision to proceed with TAVI was determined by consensus at a multidisciplinary team meeting.
Statistical Analysis
Associations between baseline characteristics and CMR RVEF (≤50% versus >50%) were tested using χ 2 tests (categorical variables), Mann-Whitney U tests (non-normal variables) or t tests (normal variables). Values were expressed as n (%), mean (95% confidence interval), or median (interquartile range [IQR]) as appropriate.
Multivariable Cox regression analysis was used to model survival after TAVI, adjusting for significant risk factors. Results are displayed as hazard ratios (HRs) and 95% confidence intervals. Model choice was informed by univariate associations, Akaike Information Criterion, and log-likelihood tests comparing nested models. Kaplan-Meier plots were used to plot adjusted estimates of survival according to RVEF ≤50% or >50%, based on the best fitting regression model.
Based on logistic regression models for predicting the outcome of death, the area under the receiver operator curve was compared for the models with and without significant CMR variables. For each model, an optimal prognostic cutoff was chosen using the Youden index,
WHAT IS KNOWN
• In the preprocedural assessment of patients being considered for transcatheter aortic valve implantation, echocardiography is used to assess valve severity, and computed tomography is used to assess potential access routes; however, whether any additional information can be provided by cardiovascular magnetic resonance imaging is currently uncertain.
WHAT THE STUDY ADDS
• This study shows that patients with poor right ventricular function, as determined by cardiovascular magnetic resonance, have higher mortality after transcatheter aortic valve implantation.
• Although larger studies will be needed, this study raises the question as to whether cardiovascular magnetic resonance should become part of the routine preprocedural work-up for transcatheter aortic valve implantation. 
Results
Patient Characteristics
The demographics and clinical characteristics of the study cohort are shown in Table 1 . The median age of the population studied was 81.0 (IQR, 74.9-85.5) years, and 50% were women. Impaired RV function (defined as RVEF<50%) was seen in 45 (23.7%) patients. In comparison with patients with normal RVSD, patients with reduced RVEF were less likely to be in sinus rhythm (42.2% versus 65.5%; P<0.001); however, there were no other significant differences in baseline clinical variables between the 2 groups. Table 2 presents the CMR parameters measured in the cohort, both overall and when divided according to the presence (n=45) or the absence (n=145) of RVSD. The median LVEF was 62% (IQR, 59%-67%) and the median indexed mass was 90 g/m 2 (IQR, 84-95 g/m 2 ). RVSD was associated with a lower LVEF (LVEF, 42% versus 69%; P<0.0001), higher LV end-diastolic (173 versus 136 mL; P=0.005) and end-systolic (96 versus 40 mL; P<0.0001) volumes, higher RV end-diastolic (144 versus 118 mL; P=0.0003) and end-systolic (85 versus 43 mL; P<0.0001) volumes, lower left (74 versus 87 mL; P=0.002) and right (60 versus 75 mL; P=0.0004) ventricular stroke volumes, and higher indexed LV mass (101 versus 85 g/m 2 ; P=0.0008).
CMR Imaging Data
On LGE-CMR, no patient was seen to have overt fibrous replacement of the RV free wall, but LV LGE was seen in 63.9% of those given gadolinium; no significant difference in gadolinium enhancement was noted between patients with and those without RVSD (69.2% versus 62.5%; P=0.526). There was a positive correlation between RVEF and LVEF measurements (r=0.584; P<0.0001), and a negative correlation between RVEF and PASP as measured by echocardiography (r=−0.3591; P<0.0001; Figure 1 ). Analysis of interobserver variability showed high levels of agreement for the measurement of RVEF (R 2 =0.96); the mean difference (95% limits of agreement) was −0.1% (4.5, −4.7; Figures in the Data Supplement).
Outcomes
Patients were followed up for a median duration of 850 days (IQR, 403-1265 days); 95.3% of surviving patients had at least 1 year of follow-up before the end of the study. A total of 64 of 190 (33.7%) patients died during this period; 21 of 45 (46.7%) patients had RVEF≤50% and 43 of 145 (29.7%) patients had RVEF>50%, as measured on CMR (P=0.035). At 1 year, 11 of 45 (24.4%) patients with RVSD had died, compared with 20 of 145 (13.8%) patients with no RVSD (P=0.091).
Predictors of All-Cause Mortality
The risk of death was estimated from Cox regression models both with and without the significant CMR variables. Univariate predictors of all-cause mortality are listed in Table 3 . Five clinical parameters were associated with mortality: diabetes mellitus (HR, 2.13; P=0.004), increased creatinine (HR, 1.00; P≤0.0001), Canadian Cardiovascular Society (CCS) class II angina (HR, 2.18; P=0.048), and both New York Heart Association III (HR, 1.99; P=0.044) and New York Heart Association IV (HR, 2.83; P=0.023) heart failure. CMR variables associated with mortality included RVEF≤50% (HR, 1.89; P=0.018), LV stroke volume (HR, 0.99; P=0.043), and LVEF<30% (P=0.019). In the multivariable model, RVEF≤50% (HR, 2.12; P=0.017) and indexed AVA (HR, 4.16; P=0.025) were independently and significantly associated with survival.
Receiver operating characteristic curve analysis showed that the optimal CMR RVEF cutoff value for predicting death was 49%. For the logistic regression model including baseline variables, the area under the receiver operating characteristic curve was 0.70 (95% confidence interval, 0.61-0.79). For the model including CMR RVEF with indexed AVA, the area under the curve was slightly improved at 0.75 (95% confidence interval, 0.67-0.84; Figure 2; P=0.036) . Based on the model including Figure 3 shows the event-free survival curves of the study population according to the presence of absence of RVSD.
Survival Curve Analysis
Using a RVEF cutoff of 50%, survival was significantly worse up to 3 years (P=0.012).
Discussion
The significant mortality benefit afforded by TAVI has led to the widespread adoption of the technique over the past decade. However, an important clinical challenge remains in ensuring that only those patients likely to gain long-term benefit from TAVI are selected for the procedure. In this study, we report on the largest cohort of TAVI patients to date who had undergone preprocedural CMR. Our results demonstrate that just under one quarter (23.7%) of patients undergoing TAVI have abnormal RVSD (RVEF≤50%), and that impaired RV function is an independent and incremental marker of adverse prognosis. These findings suggest that the accurate assessment of RVEF, as can be performed by CMR, may be capable of informing the long-term survival of patients undergoing TAVI. CMR offers several advantages with respect to TAVI assessment, including measurement of ventricular volumes and mass, planimetry of the aortic valve, and sizing of the aortic annulus. 13 Specifically, about RV function, the ability to image in multiple planes and 3D volume acquisition provided by CMR alleviates the need for geometric assumptions on RV shape. 19 Furthermore, balanced steady-state free precession cine acquisitions produce high-spatial resolution images with excellent discrimination between blood and endocardium, 20 which is important in the highly trabeculated RV to obtain accurate endsystolic and end-diastolic measurements. 21 The high accuracy and reproducibility of CMR estimates of RV volumes and EF have been extensively validated, albeit predominantly in healthy individuals. 22 However, CMR often cannot be used in patients with permanent pacemaker devices although several magnetic resonance imaging-compatible devices are now available. Our group has previously shown that normal RV CMR parameters vary according to sex, age, and body surface area. 20 In this study, we defined RVSD according to our normal clinical value of RVEF≤50%; this is similar to the optimal cutoff value (as defined by receiver operating characteristic curve analysis) of 49%. Importantly, patients with poor RV function had similar clinical characteristics to patients with normal RV function. However, a comparison of CMR parameters showed that reduced RV function was associated with reduced LV function, greater end-diastolic and end-systolic volumes (both LV and RV), and increased LV mass. Therefore, by accurately diagnosing poor RV function, CMR seems capable of identifying those patients with the worst overall cardiac function. This is in keeping with previous publications, which have suggested that RVSD may be a final common pathway in heart failure progression. 23 The pathophysiological cause of this association is not yet known, but many potential mechanisms have been proposed, including ventricular interdependence 23, 24 Several reports have documented the prognostic importance of RVSD in other cardiac pathologies. [24] [25] [26] [27] For example, impaired RVEF has been shown to be an important prognostic factor in heart failure; specifically, Gulati et al 24 demonstrated that poor RV function is an independent marker of worse prognosis in patients with dilated cardiomyopathy. Although relatively few studies have examined the role of RV dysfunction in patients with aortic stenosis, in a study of 50 consecutive patients undergoing corrective mitral or aortic surgery, Haddad et al 28 identified RV fractional area change as a marker of poor prognosis. More recently, Galli et al 29 published an echocardiographic study of 200 patients with severe aortic stenosis and found a similar prevalence of RV dysfunction to that of our cohort (24%). The same authors also described that RV dysfunction, as defined by a tricuspid annular plane systolic excursion of <18 mm, was associated with poorer cardiovascular outcomes. However, quantitative assessment of RVEF was not undertaken. Transthoracic echocardiography is limited in the assessment of RVEF, owing to the asymmetrical crescentic shape of the RV. 24 To the best of our knowledge, the present study is, therefore, the first to show that CMR assessment of RVEF predicts outcome in patients undergoing TAVI.
Pulmonary hypertension and reduced RV function are known to increase the risk of noncardiac surgery, and previous reports have confirmed pulmonary hypertension as an independent marker of adverse prognosis after TAVI. 30 However, to the best of our knowledge, this is the first description of RVSD as an independent predictor of mortality after TAVI. The finding of higher pulmonary artery pressures in patients with RVSD, and a negative correlation between RVEF and pulmonary artery pressure, is in keeping with previous literature showing that RV dysfunction is a predictor of clinical outcomes in patients with pulmonary hypertension. 26 Therefore, despite a reported improvement in pulmonary artery pressures after the TAVI, 31 long-term prognosis may be limited by the presence of RV systolic dysfunction.
Whether TAVI or surgical AVR impact on RV function remains uncertain. Kempny et al 32 found no deterioration in several echocardiographic measurements of RV function after TAVI, but found that surgical AVR caused a worsening of RV function. More recently, Crouch et al 33 performed CMR of 47 patients within 2 weeks of TAVI or surgical AVR and found no significant change in LV function after surgical AVR; in contrast, a significant reduction in RVEF was seen in the TAVI group after the procedure. Although the detrimental effects of pericardiotomy and cardiopulmonary bypass could explain a deterioration in RVEF after surgery, the exact mechanism of any decline in RV function after TAVI remains uncertain. Further serial imaging studies are needed to clarify this issue; however, our data would suggest that poor RV function should be recognized as influencing TAVI outcomes in the same way that it is recognized as influencing outcomes after surgical AVR. 28, 34 
Limitations
First, although the time between CMR scanning and the time of TAVI varied in this study, the association between RVEF and outcome was found whether analysis was made from the time of the scan or the time of the TAVI procedure.
Second, this study is selected in that patients with very poor LV function may have been declined for TAVI. However, this represents contemporary practice, and our study serves to underline how both LV and RV function must be considered when making the final decision for TAVI.
Finally, although the results of this 190 patient study suggest that patients with low RVEF have poorer outcomes after TAVI, this finding should be investigated further in a larger group of patients with severe aortic stenosis.
Conclusions
RVEF, as measured on preprocedural CMR, is present in almost 1 in 4 patients undergoing TAVI and is an independent predictor of long-term mortality. CMR assessment of RV function may be important in the evaluation and risk stratification of patients undergoing TAVI.
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